A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Authors :: Ng, King Pan
Hillmer, Axel M.
Chuah, Charles T.H.
Juan, Wen Chun
Ko, Tun Kiat
Teo, Audrey S.M.
Ariyaratne, Pramila N.
Takahashi, Naoto
Sawada, Kenichi
Fei, Yao
Soh, Sheila
Lee, Wah Heng
Huang, John W.J.
Allen, Jr., John C.
Woo, Xing Yi
Nagarajan, Niranjan
Kumar, Vikrant
Thalamuthu, Anbupalam
Poh, Wan Ting
Ang, Ai Leen
Mya, Hae Tha
How, Gee Fung
Yang, Li Yi
Koh, Liang Piu
Chowbay, Balram
Chang, Chia-Tien
Nadarajan, Veera S.
Chng, Wee Joo
Than, Hein
Lim, Lay Cheng
Goh, Yeow Tee
Zhang, Shenli
Poh, Dianne
Tan, Patrick
Seet, Ju-Ee
Ang, Mei-Kim
Chau, Noan-Minh
Ng, Quan-Sing
Tan, Daniel S.W.
Soda, Manabu
Isobe, Kazutoshi
Nothen, Markus M.
Wong, Tien Y.
Shahab, Atif
Ruan, Xiaoan
Cacheux-Rataboul, Valere
Sung, Wing-Kin
Tan, Eng Huat
Yatabe, Yasushi
Mano, Hiroyuki
Soo, Ross A.
Chin, Tan Min
Lim, Wan-Teck
Ruan, Yijun
Ong, S. Tiong
Source :: Nature Medicine. April, 2012, Vol. 18 Issue 4, p521, 11 p.
Publication Year :: 2012
Abstract: Tyrosine kinase inhibitors (TKIs) elicit high response rates among individuals with kinase-driven malignancies, including chronic myeloid leukemia (CML) and epidermal growth factor receptor-mutated non-small-cell lung cancer (EGFR NSCLC). However, the [...]

Subjects :: Tumor proteins -- Physiological aspects -- Genetic aspects -- Research
Antineoplastic agents -- Dosage and administration -- Genetic aspects -- Research
Genetic polymorphisms -- Physiological aspects -- Research -- Genetic aspects
Protein tyrosine kinase -- Physiological aspects -- Genetic aspects -- Research
Antimitotic agents -- Dosage and administration -- Genetic aspects -- Research
Biological sciences
Health

Full Text Access

Tools